ABO blood group-mediated VWF kinetics associated with early phenotypic divergence in dizygotic twins with severe hemophilia A.

FIXa-triggered thrombin generation correlates with FVIII levels less than 1% in reconstituted plasma mimicking samples obtained from patients with severe hemophilia A.

An analysis of attitudes toward gene therapy in people with severe hemophilia in Germany, a survey-based cross-sectional study.

Mechanisms of thrombin inhibition by protein S and the TFPIα-fVshort-protein S complex.

In Vitro Spiking Comparison of Coagulation Potential Between Emicizumab and Mim8 in Whole Blood and Plasma From a Single Patient With Severe Hemophilia A Receiving FVIII Prophylaxis and Warfarin.

Treatment With Valoctocogene Roxaparvovec in a Patient With Severe Hemophilia A Led to Sustained Normal FVIII Levels.

Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity.

Monochorionic diamniotic twin brothers with severe hemophilia A: a case report.

Machine learning estimation of FVIII pharmacokinetic parameters in Chinese children with severe Hemophilia A.

Pharmacokinetics of Factor VIII in Adults with Hemophilia: A 24-Hour Single-Sample Study Focused on Trough Levels.

Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis.

Corrigendum to 'Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors': [Research and Practice in Thrombosis and Haemostasis Volume 9, Issue 6, August 2025, 103006].

Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays.

Severe hemophilia A with inhibitors and pancreatic cancer - when emicizumab is not enough.

Factors contributing to the development of hemophilic arthropathy: A real-world study.

rFVIIIa-platelet binding enhances platelet procoagulant activity independently of thrombin generation.

Human leukocyte antigen alleles associated with inhibitor development in severe hemophilia A: analysis of the "My Life, Our Future" hemophilia A cohort.

The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders.

Complex Triple Deformity of the Knee Managed with Knee Arthrodesis in a Severe Hemophilia A Patient: A Case Report.

Case Report: Intracranial hemophilic pseudotumor mimicking an aggressive neoplasm: a rare skull-invasive presentation.

Noncarrier mothers of hemophilia A patients with Intron 22 inversions often have other rearrangements.

Recurrence of FVIII Inhibitor during Surgery in a Patient with Severe Hemophilia A Receiving Emicizumab Prophylaxis.

Hemophilic pseudotumor in the hand: a case report and literature review.

Eight-Week Resistance Training and Manual Therapy in Young Patients with Severe Hemophilia: A Case Series Evaluating Functional, Imaging, and Immunological Outcomes.

AOZORA study: 3-year interim analysis of safety and joint health in pediatric people with hemophilia A receiving emicizumab prophylaxis.

Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial.

Impact of Inhibitor Development on the Cost Effectiveness of Prophylactic Treatment with Recombinant Factor VIII in Previously Untreated Patients with Severe Hemophilia A.

Case Report of acupotomy release combined with manual release under anesthesia for adhesions after unilateral total knee arthroplasty in a patient with hemophilia A.

The impact of individualized prophylactic treatment based on pharmacokinetic parameters on the prognosis of patients with severe hemophilia A.

FRONTIER1 multiple ascending dose extension: a safety, tolerability, pharmacokinetics, and pharmacodynamics study of Mim8 in people with hemophilia A.

Large deletions in the F8 gene predict immune tolerance induction failure in people with severe hemophilia A.

From pharmacokinetic-guided FVIII prophylaxis to low-dose Emicizumab prophylaxis: a pilot study revealed a flush of hope.

Emicizumab in Severe Hemophilia A: Clinical and Patient Determinants of Transition Within a Standardized Program.

Cost Effectiveness of Efanesoctocog Alfa Versus Factor VIII Extended Half-Life in Adolescent and Adult Patients with Hemophilia A in the USA.

Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors.

Silent Avascular Necrosis of the Femoral Head in Severe Hemophilia A: A Case Report.

MHC class II presentation of FVIII-AnnexinA5 fusion proteins internalized by antigen presenting cells.

Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors' Organisation.

Long-Term Joint Function and Quality of Life Following Emicizumab Prophylaxis in Severe Hemophilia A: A Single-Center Study From Goa, India.

Tertiary prophylaxis with extended half-life factor prophylaxis: a model to reduce disability in low- and middle-income countries.

Estimated Long-Term Durability of Valoctocogene Roxaparvovec Treatment in Male patients with Severe Hemophilia A: An Extrapolation of Clinical Data.

Comparative Effectiveness of Valoctocogene Roxaparvovec and Efanesoctocog Alfa in the Treatment of Severe Hemophilia A: A Matching-Adjusted Indirect Comparison of Bleeding Frequency.

Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US cohort study.

Factor VIII Pharmacokinetics in Mexican Patients with Hemophilia A.

Long-Term Anticoagulation in a Severe Hemophilia A Patient Receiving Efanesoctocog Alpha Prophylaxis: A Case Report.

Impact of Severe Hemophilia on Costs and Quality of Life in South American Men: Findings From the CHESS LATAM Study.

Missense and nonsense mutations and inhibitor development in patients with hemophilia A and B.

Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously untreated or minimally treated children with hemophilia A or B.

Significant Bleeding Event Secondary To Maxillary Labial Frenectomy.

Application of capillary gel electrophoresis in detection of Factor VIII gene intron 22 inversion of hemophilia A.

Risk factors for joint bleeding in severe hemophilia A and B: analysis of the Community Counts longitudinal surveillance cohort.

The role of interleukin-10 gene variants in inhibitor development in hemophilia: A meta-analysis.

Assessment of Mandibular Trabecular Bone by Fractal Analysis on Digital Panoramic Radiograph in Patients with Inherited Bleeding Disorder.

Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis.

Exploring the Relationship Between Personalization of Care and Participation in Sport Activities Among People with Severe Hemophilia A Across Europe: Post Hoc Analysis of the CHESS II Study.

Regional brain volumes and their relationship to neurocognitive outcomes in children with severe hemophilia A.

Progressive cephalohematoma in a neonate revealing severe hemophilia a owing to intron 22 inversion: a case report.

Predictors of immune tolerance induction success in 231 children with severe hemophilia A with high-titer inhibitors - lessons learned from the PedNet prospective cohort study.

Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial.

The interleukin-33 receptor (ST2) is a novel therapeutic target to attenuate the progression of hemophilic arthropathy.

Impact of the Individualized 4-Year Physiotherapy on the Musculoskeletal System and Quality of Life of Patients With Severe Hemophilia A With Inhibitors.

Silent progression of hemophilic arthropathy of the elbow: case reports of three pediatric patients.

Comparison of Magnetic Resonance Imaging Scales for Assessment of Interval Changes of Arthropathy in Boys with Severe Hemophilia.

Hospitalization for child physical abuse before hospitalization for osteogenesis imperfecta or severe hemophilia: A nationwide cohort study in France.

Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial.

Rapid Maxilla Expansion Technique in Patients With Severe Hemophilia Type A: Treatment Protocol.

Safety and efficacy of marstacimab in patients with hemophilia A and B: a systematic review and meta-analysis.

First-in-human pharmacokinetic, safety, and preliminary efficacy studies of single- and multiple-dose FRSW117, a novel PEGylated recombinant factor VIII-Fc fusion protein with an extended half-life, in patients with severe hemophilia A.

Recombinant Adeno-Associated Virus Integration Profiles in Nonhuman Primates and Gene Therapy Participants after Treatment with Valoctocogene Roxaparvovec.

A repeated time-to-event model for personalized treatment of patients with hemophilia A based on individual bleeding risk.

Life-Threatening Pharyngolaryngeal Hematoma in a Patient With Hemophilia A.

Real-World Evidence on Joint Condition in Non-Severe Hemophilia A Patients: A Multicenter Study.

Anchoring the Hemophilia Joint Health Score for Conventional Value Assessment in the Care of People Living with Severe Hemophilia A.

Single-cell sequencing on PBMCs from patients with HA and HB with inhibitors reveals different immune responses to FVIII and FIX.

In vitro effects of Mim8 and combined Mim8-bypassing therapy on thrombin generation, thromboelastography and fibrin clot ultrastructure.

Prevalence and Clinical Correlation of Intron 22 Inversion in Hemophilia A in Northeast India.

Hematopoietic stem cell transplantation in a newborn suffering from severe combined immunodeficiency and severe hemophilia A: a case report and review of the literature.

Generation of a Severe Hemophilia A Humanized Mouse Model Capable of Inducing an Anti-FVIII Immune Response.

Summary for Patients: Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in People Living With Severe Hemophilia A.

Prophylactic Weekly Efanesoctocog Alfa Versus Standard-Care Factor VIII in People Living With Severe Hemophilia A : A Cost-Effectiveness Analysis.

Ex vivo lentiviral gene therapy for severe hemophilia A: an alternative to recombinant adeno-associated viral-based strategies?

Real-world bleeding rates on emicizumab: the value of using nationwide digital treatment diary data in clinical research.

Quality of life of children and adolescents with hemophilia receiving low-dose prophylactic treatment.

Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A.

An Observational Study of Glycopegylated Extended Half-Life Factor Prophylaxis in Hemophilia A and B in a Tertiary Care Center in India.

Annualized bleeding rate in hemophilia A patients in Brazil: a systematic review.

Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group.

Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time-To-Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A.

Early diagnosis and prophylactic treatment with emicizumab in premature infants with severe hemophilia A.

A comparison of My Precise Dose and WAPPS-Hemo as dosing tools for optimizing prophylaxis in children with hemophilia A treated with BAY 81-8973.

Comparative Efficacy of Recombinant FVIII and Recombinant FVII Biosimilars in Severe Hemophilia A.

[Application value of thromboelastography in assessing coagulation function in children with severe hemophilia A after emicizumab therapy: a single-center study].

A plain language summary on indirectly comparing bleeding after valoctocogene roxaparvovec gene therapy to bleeding with emicizumab prophylaxis.

Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance.

Regulation of immune responses to therapeutic factor VIII by transplacental delivery of Fc-fused immunodominant factor VIII domains or peptides.

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study.

Bleeding Episodes in Patients With Haemophilia B Receiving Prophylactic Factor IX Treatment: A Systematic Review and Meta-Analysis.

Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study.

Immune tolerance induction for inhibitor eradication in nonsevere hemophilia A: a case series.

A 5-Year Single-center Experience on the Use of Emicizumab Prophylaxis in Children With Severe Hemophilia A With and Without Factor VIII Inhibitors.

Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial.

Tolerance to factor VIII in the era of nonfactor therapies: immunologic perspectives and a systematic review of the literature.

Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study.

Surgical Excision of a Hemophilic Pseudotumor Causing Vascular Impingement in a Patient with Severe Hemophilia A: A Case Report.

Evaluation of discrepancy between clot-based and chromogenic factor IX coagulation assays in non-severe hemophilia B patients and identification of the causing mutations.

Marstacimab: First Approval.

Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial.

Ex vivo evaluation of the effect of plasma-derived factor VIII/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis.

Dental management of people with congenital hemophilia: An integrative review of case reports and case series from a global scenario.

Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial.

Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A.

Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study.

Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B.

A clot waveform analysis-based system for differential diagnosis of prolonged activated partial thromboplastin time in plasma samples.

Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION).

Combined adductor canal (ACB) and sacral erector spinae plane (S-ESP) blocks for total knee arthroplasty pain in hemophilic arthropathy.

Neonatal Presentation of Severe Hemophilia A: An Original Case Report and a Literature Review.

Prediction of the chance of successful immune tolerance induction in persons with severe hemophilia A and inhibitors: a clinical prediction model.

Combination of bolus and continuous infusion of factor VIII in a patient with severe hemophilia A undergoing on-pump coronary artery bypass graft surgery.

Freedom From Bleeds With Low-Dose Emicizumab Prophylaxis in Inhibitor-Positive Hemophilia A.

Development and internal validation of a clinical prediction model for individualized dosing of BAY 81-8973, A full-length recombinant factor VIII, in pediatric patients with haemophilia A.

[Pharmacokinetic Study of Coagulation Factor Ⅷ in Adults with Severe Hemophilia A].

Factor X consumption attenuates the coagulation effect of emicizumab: a case of severe hemophilia A treated with emicizumab and factor VIII-bypassing agents.

Inverse Shifting-PCR Modified by Capillary Electrophoresis for Detecting F8 int22h and int1h Inversions in Severe Hemophilia A Patients and Probable Carriers.

Saliva of persons with hemophilia A triggers coagulation via extrinsic tenase complexes.

Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors.

Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Moderate or Severe Hemophilia A in China.

Patient Experience With Efanesoctocog Alfa for Severe Hemophilia A: Results From the XTEND-1 Phase 3 Clinical Study Exit Interviews.

A Novel Murine Model Enabling rAAV8-PC Gene Therapy for Severe Protein C Deficiency.

Severe Hemophilic Arthropathy of the Knee: MRI Has Its Place.

CHIEF: A retrospective self-control study of children with severe hemophilia A without inhibitors comparing emicizumab to FVIII prophylaxis.

Emicizumab in Children with Severe Hemophilia A.

Relationship between mutations in severe hemophilia A and risk of inhibitor development: A large single-center study.

Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life.

Switching hemophilia A patients to rVIII-SingleChain: The Iberian experience.

Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk.

Comprehensive Screening of Genetic Variants in the Coding Region of F8 in Severe Hemophilia A Reveals a Relationship with Disease Severity in a Colombian Cohort.

Patient and Caregiver Preferences for Hemophilia A Treatment in Taiwan: A Discrete Choice Experiment.

Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review.

Integrating musculoskeletal ultrasound as a shared decision-making tool in hemophilia care: observations from a 3-year study.

Large deletions and small insertions and deletions in the factor VIII gene predict unfavorable immune tolerance induction outcome in people with severe hemophilia A and high-responding inhibitors.

Peripheral Blood Lymphocyte Subsets in Factor VIII Inhibitor-Positive Patients with Severe Hemophilia A: A Case-Control Study.

The longitudinal kinetics of AAV5 vector integration profiles and evaluation of clonal expansion in mice.

[Long-term health-related quality of life and related factors in children with severe hemophilia A who received regular low-dose prophylaxiss].

An Inhibitory Single-Domain Antibody against Protein Z-Dependent Protease Inhibitor Promotes Thrombin Generation in Severe Hemophilia A and FXI Deficiency.

International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology.

Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS).

Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A.

Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.

Adult People with Hemophilia A Have Low Annualized Bleeding Rate, However the Arthropathy Remains a Burden: A Retrospective Cohort Study.

Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans.

COVID-19 in the Setting of HIV and Severe Hemophilia A: A Case Report.

Low-dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor-titer below 200 BU/mL.

Physical Activity, Bleedings and Quality of Life in Subjects with Haemophilia A without Inhibitors-A Multicenter, Observational Italian Study with a Wearable Device.

[Minimally invasive treatment of varicose veins of lower extremities in a patient with hemophilia A (case report)].

Optimizing liver health before and after gene therapy for hemophilia A.

Walking ability in adults with severe hemophilia: A cross-sectional study.

Prediction of inhibitor development in previously untreated and minimally treated children with severe and moderately severe hemophilia A using a machine-learning network.

Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A.

Practical challenges associated with efanesoctocog alfa (ALTUVIIIO) prophylaxis in a 19-month-old male with severe hemophilia A.

Simoctocog alfa (Nuwiq®) in children: early steps in life's journey for people with severe hemophilia A.

Management of traumatic dental injuries in a hemophiliac patient: A challenge! Case report with nine years follow-up.

Economic and Humanistic Burden of Moderate and Severe Hemophilia A and B in Spain: Real-World Evidence Insights from the CHESS II Study.

Blood pressure responses to handgrip exercise but not apnea or mental stress are enhanced in women with a recent history of preeclampsia.

Incidence of deep venous thrombosis in patients with hemophilia undergoing bilateral simultaneous total knee arthroplasty: a retrospective cohort study.

Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor.

Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A: correlation with "Inhibitor" formation.

Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.

Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.

Assessment of jaw bone mineral density, resorption rates, and oral health in patients with severe hemophilia: a case-control study.

Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A.

Evaluation of an e-Learning Program for Community Pharmacists for Dispensing Emicizumab (Hemlibra) in France: Nationwide Cross-Sectional Study.

Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.

Prophylactic Treatment of Children with Hemophilia in Sweden.

Whole F8 gene sequencing identified pathogenic structural variants in the remaining unsolved patients with severe hemophilia A.

Emicizumab promotes factor Xa generation on endothelial cells.

Comprehensive domain-specific analysis and immunoglobulin G profiling of anti-factor VIII antibodies using a bead-based multiplex immunoassay.

Vector integration and fate in the hemophilia dog liver multiple years after AAV-FVIII gene transfer.

[Successful immunosuppressive therapy in female hemophilia A developing inhibitor after perioperative administration of factor VIII products].

Epidemiological profile of hemophilia A in Karbala-Iraq.

Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single-center experience in Bangladesh.

[Removal of a dermoid cyst of the floor of the mouth in a patient with severe hemophilia A].

The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study.

Pharmacokinetic-Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate.

Concomitant large deletion and de novo duplication of factor VIII gene in an Indian patient with severe Hemophilia A.

The influence of dead space in blood sampling needle on FVIII level and pharmacokinetic profiles in children with hemophilia.

A Response to: Letter to the Editor Regarding "Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China".

Immune tolerance promotion by LSEC-specific lentiviral vector-mediated expression of the transgene regulated by the stabilin-2 promoter.

Comparison Pharmacokinetic Dosing Tools in Hemophilia A Children.

Mutation detection and inhibitor analysis of 43 children with severe hemophilia A in a single center: three novel mutations.

A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trial.

Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment.

Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU.

Race, ethnicity, and immune tolerance induction in hemophilia A in the United States.

Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada.

Successful Ultrasound-Guided Spinal Anesthesia in a Patient With Severe Hemophilia A Undergoing Total Hip Arthroplasty.